NSE Announcements Details
YOU ARE ON :
HOME
/
MARKETS
/
Company Information
/
NSE Announcements Details
Equity Analysis
Gainers & Losers
New Highs & Lows
52 Week High & Low
Advances & Declines
Top Value
Company Information
Detailed Quotes
Company Background
Board Of Directors
Balance Sheet
Profit & Loss
Quarterly Results
Key Financial Ratios
Share Price Monthly
Intraday / EOD charts
Corporate Action
BSE Announcements
NSE Announcements
Board Meetings
Book Closure
Bonus Issues
Rights Issues
De-Listed Shares
Market Turnover
Change Of Name
Split Of Face Value
News Analysis
Hot Pursuit
Foreign Markets
Other Markets
Corporate News
Market Beat
Economy News
Corporate Results
Stock Alert
Pre-Session Commentary
Mid-Session Commentary
End-Session Commentary
Other Markets
ADR Prices
Initial Public Offering
Forthcoming Issues
Open Issues
Closed Issues
New Listing
Basis of Allotment
Draft Prospectus
New Issue Monitor
Equity Analysis
Gainers & Losers
New Highs & Lows
52 Week High & Low
Advances & Declines
Top Value
Company Information
Detailed Quotes
Company Background
Board Of Directors
Balance Sheet
Profit & Loss
Quarterly Results
Key Financial Ratios
Share Price Monthly
Intraday / EOD charts
Corporate Action
BSE Announcements
NSE Announcements
Board Meetings
Book Closure
Bonus Issues
Rights Issues
De-Listed Shares
Market Turnover
Change Of Name
Split Of Face Value
News Analysis
Hot Pursuit
Foreign Markets
Other Markets
Corporate News
Market Beat
Economy News
Corporate Results
Stock Alert
Pre-Session Commentary
Mid-Session Commentary
End-Session Commentary
Other Markets
ADR Prices
Initial Public Offering (IPO)
Forthcoming Issues
Open Issues
Closed Issues
New Listing
Basis of Allotment
Draft Prospectus
New Issue Monitor
Back
Lupin Limited - Press Release
Lupin Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States".